HµRELflowTMThe metabolic competency of HµREL®‘s patented flow-based (i.e., perfusion-based) biochips and instrumentation enables parent compound clearance and metabolite generation significantly greater than that afforded by hepatocytes cultured under static conditions, when presented to compounds that invoke the broad range of Phase I and Phase II metabolic enzymes. HµREL®‘s flow-based metabolic competency has been shown stable for 14 days and longer.
U.S. Patent No’s. 5,612,188; 7,288,405; 8,030,061; other patents pending
HµRELviralTMLong-enduring infectious liver disease platform
HµRELfluxTMa new, patent-pending